BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33177192)

  • 1. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
    Li H; Sun H; Tao M; Han Q; Yu H; Li J; Lu X; Tong Q; Pu J; Sun Y; Liu L; Liu J; Sun H
    J Virol; 2024 Mar; 98(3):e0112923. PubMed ID: 38305155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
    Rijal P; Wang BB; Tan TK; Schimanski L; Janesch P; Dong T; McCauley JW; Daniels RS; Townsend AR; Huang KA
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31748388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.
    Horimoto T; Takada A; Fujii K; Goto H; Hatta M; Watanabe S; Iwatsuki-Horimoto K; Ito M; Tagawa-Sakai Y; Yamada S; Ito H; Ito T; Imai M; Itamura S; Odagiri T; Tashiro M; Lim W; Guan Y; Peiris M; Kawaoka Y
    Vaccine; 2006 Apr; 24(17):3669-76. PubMed ID: 16378663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
    Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
    J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content.
    Abt M; de Jonge J; Laue M; Wolff T
    Vaccine; 2011 Jul; 29(32):5153-62. PubMed ID: 21624413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.
    Isakova-Sivak I; Chen LM; Bourgeois M; Matsuoka Y; Voeten JT; Heldens JG; van den Bosch H; Klimov A; Rudenko L; Cox NJ; Donis RO
    Clin Vaccine Immunol; 2014 May; 21(5):722-31. PubMed ID: 24648485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
    Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
    Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
    Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
    Tang XC; Lu HR; Ross TM
    Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus.
    Furey C; Scher G; Ye N; Kercher L; DeBeauchamp J; Crumpton JC; Jeevan T; Patton C; Franks J; Rubrum A; Alameh MG; Fan SHY; Phan AT; Hunter CA; Webby RJ; Weissman D; Hensley SE
    Nat Commun; 2024 May; 15(1):4350. PubMed ID: 38782954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice.
    Zheng L; Wang F; Yang Z; Chen J; Chang H; Chen Z
    BMC Infect Dis; 2009 Feb; 9():17. PubMed ID: 19216752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.
    Chang H; Huang C; Wu J; Fang F; Zhang W; Wang F; Chen Z
    Virol J; 2010 Aug; 7():197. PubMed ID: 20727202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.
    Yang P; Duan Y; Zhang P; Li Z; Wang C; Dong M; Tang C; Xing L; Gu H; Zhao Z; Liu X; Zhang S; Wang X
    PLoS One; 2012; 7(1):e30252. PubMed ID: 22279575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.
    Pappas C; Matsuoka Y; Swayne DE; Donis RO
    Clin Vaccine Immunol; 2007 Nov; 14(11):1425-32. PubMed ID: 17913860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.
    Steel J; Lowen AC; Pena L; Angel M; Solórzano A; Albrecht R; Perez DR; García-Sastre A; Palese P
    J Virol; 2009 Feb; 83(4):1742-53. PubMed ID: 19073731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine.
    Carter DM; Bloom CE; Kirchenbaum GA; Tsvetnitsky V; Isakova-Sivak I; Rudenko L; Ross TM
    Vaccine; 2015 Jan; 33(1):108-16. PubMed ID: 25448100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.